<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156958</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2165</org_study_id>
    <nct_id>NCT04156958</nct_id>
  </id_info>
  <brief_title>Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma</brief_title>
  <acronym>FSTAMBTA</acronym>
  <official_title>An Exploratory Study to Evaluate Efficacy and Safety of Fruquintinib as Second-line Treatment for Patients With Advanced or Metastatic Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective, multicenter, single-arm design study is to evaluate the efficacy and safety
      of fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who
      failed first-line chemotherapy with gemcitabine, platinum/S-1, and albumin paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biliary tract cancer arises from the epithelial cells of the bile ducts. Until nowadays, no
      standard second-line treatment has been established following recurrence from the first-line
      treatment. Angiogenesis plays a key role in the carcinogenesis and development of biliary
      tract adenocarcinoma. Studies have shown that VEGF is expressed in more than 50% of biliary
      tract adenocarcinoma, and microvessel density is significantly associated with tumor
      progression, metastasis, and prognosis. Fruquintinib (trade name: Elunate) is a novel small
      molecule tyrosine kinase inhibitor. It is currently being evaluated in clinical trials for
      multiple cancers including lung cancer, gastric cancer and colorectal cancer and showed
      strong anti-tumor activity. The aim of the study is to evaluate the efficacy and safety of
      fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who failed
      first-line chemotherapy.

      The trial is a prospective, multicenter, single-arm design study. Eligible participants with
      advanced or metastatic biliary tract adenocarcinoma who have failed first-line chemotherapy
      with gemcitabine, platinum/S-1, and albumin paclitaxel. The study will explore the efficacy
      and safety of second-line treatment with fruquintinib, and quality of life during treatment.
      Tumor assessment was performed every 8 weeks as defined by RECIST 1.1. Blood samples will be
      collected at baseline (before treatment) and 2 weeks after treatment, and cfDNA will be
      collected for gene detection analysis to evaluate the correlation between different gene
      mutations and their changes and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as the time from the date of enrollment to the first date of documented objective progression disease or of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as the percentage of patients who have a partial or complete response to therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as the percentage of patients who have achieved complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined as the time from the date of enrollment to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>3 months after the last administration of fruquintinib</time_frame>
    <description>Defined by treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Biliary Tract Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Fruquintinib Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fruquintinib, 5 mg once daily for 21 days, followed by 7 days off (28 days/cycle) treatment until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.</description>
    <arm_group_label>Fruquintinib Arm</arm_group_label>
    <other_name>Elunate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  （1） Patients must be able to understand and be willing to sign the written informed
             consent form. A signed informed consent form must be appropriately obtained prior to
             the conduct of any trial-specific procedure.

             （2） Age ≥18 years. （3） Histologically or cytologically confirmed diagnosis of advanced
             or metastatic biliary tract adenocarcinoma （4） First-line chemotherapy failed (tumor
             progression or intolerable adverse events).

             （5） The expected survival is no less than 3 months. （6） ECOG PS≤1. （7） At least one
             measurable lesion according to RECIST 1.1 criteria. （8） Adequate organ function
             including the following:

               -  Total bilirubin ≤3 times upper limit of normal (ULN),

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤5×ULN,

               -  Alkaline phosphatase≤2.5×ULN (If the tumor invaded the liver, ≤5×ULN),

               -  Serum creatinine≤1.5×ULN,

               -  Serum amylase and lipase≤1.5×ULN,

               -  International standardized ratio (INR)/partial prothrombin time (PTT)≤1.5×ULN;

               -  Platelet count ≥ 75,000 /mm3.

               -  Hemoglobin (Hb) ≥ 9 g/dL.

               -  Absolute neutrophil count (ANC) ≥ 1500/mm3. （9） Strict contraception.

        Exclusion Criteria:

          -  （1） Unable to comply with the research program or procedures. （2） Undergoing other
             drug clinical trials, or has participated in any drug clinical trials one month before
             enrollment.

             （3） Uncontrolled hypertension (systolic pressure ≥140 mm Hg or diastolic pressure ≥ 90
             mm Hg on repeated measurement) despite optimal medical management.

             （4） Active or clinically significant cardiac disease:

               -  Congestive heart failure &gt; New York Heart Association (NYHA ) class 2;

               -  Active coronary artery disease;

               -  Arrhythmias requiring treatment other than β-blocker or digoxin;

               -  Unstable angina (with angina symptoms at rest), new angina within 3 months before
                  enrollment, or new myocardial infarction within 6 months before enrollment （5）
                  Evidence or history of bleeding diathesis or coagulopathy. （6） Grade 3 bleeding
                  events 4 weeks before enrollment. （7） Thromboembolism or arteriovenous events,
                  such as cerebrovascular events (including transient ischemic attack), deep vein
                  thrombosis or pulmonary embolism, occurred 6 months before enrollment.

                  （8） Currently taking anticoagulants. （9） Other tumors that have not been treated
                  or exist at the same time, except carcinoma in situ of the cervix, treated basal
                  cell carcinoma or superficial bladder tumor. If the tumor has been cured and no
                  evidence of disease has been found for more than 3 years, the patient can be
                  enrolled. All other tumors must be treated at least 3 years before enrollment.

                  （10） Patients with pheochromocytoma. （11） Patients with a history of HIV
                  infection or active hepatitis B/C. （12） Ongoing &gt; level 2 infection. （13）
                  Symptomatic brain metastasis or meningioma. （14） Unhealed wounds, ulcers or
                  fractures. （15） Renal failure patients requiring blood or peritoneal dialysis.
                  （16） Dehydration≥ 1 grade （17） Epileptic that need medication （18） Proteinuria≥ 3
                  grade (Urinary protein &gt; 3.5g / 24hour) （19） Active, symptomatic interstitial
                  pneumonia, pleural or ascites that causes dyspnea (dyspnea ≥ 2 grade) （20）
                  History of organ transplantation. (including corneal transplantation). （21）
                  Allergic to research drugs or similar drugs, or suspected allergies. （22）
                  Malabsorption patients. （23） Pregnant or lactating women. （24） Investigator
                  believes that patients who are not suitable for the study. （25） Medical,
                  psychological or social conditions can affect the recruitment of patients and
                  evaluation for study results.

                  （26） Other anti-tumor therapy (chemotherapy, radiotherapy, surgery,
                  immunotherapy, biotherapy, chemoembolization) other than investigator drugs
                  (fruquintinib). Palliative external irradiation for non-target lesions is
                  allowed.

                  （27） Previously used fruquintinib or other angiogenesis inhibitors. （28） Major
                  surgery 4 weeks before recruitment, open biopsy or major trauma surgery.
                  (excluding biliary stents, or percutaneous biliary drainage) （29） Treatment with
                  anti-tumor Chinese herbal medicine. （30） History of allogeneic blood transfusion
                  within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiu Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiu Li, M.D.</last_name>
    <phone>+86-28-85422589</phone>
    <email>fbqiu9@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengfei Zhang, M.D.</last_name>
    <phone>+86-17828163584</phone>
    <email>fly_121988@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital 5th Medical Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhen Zeng, M.D.</last_name>
      <phone>+86-15010540233</phone>
      <email>zengzhen1970@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhen Zeng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Tumor Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yudong Wang, M.D.</last_name>
      <phone>+86-15931166600</phone>
      <email>wyd_999@126.com</email>
    </contact>
    <investigator>
      <last_name>Yudong Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haibo Lu, M.D.</last_name>
      <phone>+86-13613657491</phone>
      <email>13613657491@126.com</email>
    </contact>
    <investigator>
      <last_name>Haibo Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yawen Gao, M.D.</last_name>
      <phone>+86-18673194699</phone>
      <email>2948390593@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yawen Gao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huizheng Bao, M.D.</last_name>
      <phone>+86-15543739999</phone>
      <email>1622930252@qq.com</email>
    </contact>
    <investigator>
      <last_name>Huizheng Bao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lijiao Zhang, M.D.</last_name>
      <phone>+86-13934598881</phone>
      <email>597121763@qq.com</email>
    </contact>
    <investigator>
      <last_name>Lijiao Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiu Li, M.D.</last_name>
      <phone>+86-28-85422589</phone>
      <email>fbqiu9@163.com</email>
    </contact>
    <investigator>
      <last_name>Qiu Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Zhen-Yu Ding</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>biliary tract adenocarcinoma</keyword>
  <keyword>fruquintinib</keyword>
  <keyword>anti-angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

